secwatch / observer
8-K filed April 16, 2025, 7:59 PM ET ticker FBIO CIK 0001429260
leadership confidence high sentiment neutral materiality 0.60

Fortress Biotech director Lucy Lu resigns from board, to become Chief Strategy Officer on April 21

Fortress Biotech, Inc.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Lucy Lu

Director
FBIO · Fortress Biotech, Inc.
Effective
2025-04-15
Filed
April 16, 2025, 7:59 PM ET
On April 15, 2025, Lucy Lu, M.D., notified Fortress Biotech, Inc. (the “ Company ”) of her resignation from the Board of Directors effective April 15, 2025.
Appointed

Lucy Lu

Chief Strategy Officer
FBIO · Fortress Biotech, Inc.
Effective
2025-04-21
Filed
April 16, 2025, 7:59 PM ET
Dr. Lu’s decision to resign from the Board of Directors was made in connection with her accepting an offer to join the Company as Chief Strategy Officer effective April 21, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Lucy Lu resigned as Director at Fortress Biotech, Inc..

Action
resigned
Role
Director
Exact text from the filing
On April 15, 2025, Lucy Lu, M.D., notified Fortress Biotech, Inc. (the “ Company ”) of her resignation from the Board of Directors effective April 15, 2025.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Lucy Lu was appointed as Chief Strategy Officer at Fortress Biotech, Inc..

Action
appointed
Role
Chief Strategy Officer
Exact text from the filing
Dr. Lu’s decision to resign from the Board of Directors was made in connection with her accepting an offer to join the Company as Chief Strategy Officer effective April 21, 2025.
View on SEC.gov

Fortress Biotech, Inc. filing history →

Source: SEC EDGAR
accession 0001558370-25-004898
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.